Interferon and ursodeoxycholic acid comb
β
Eveline Boucher; HervΓ© Jouanolle; Patrice Andre; Annick Ruffault; Dominique Guya
π
Article
π
1995
π
John Wiley and Sons
π
English
β 744 KB
Because 70% to 75% of patients with chronic hepatitis C either do not respond to or relapse after interferon (IFN) therapy, and because ursodeoxycholic acid (UDCA) has been shown to reduce aminotransferase lev-TOLOGY 199% 21 :322-327.